儿童中心静脉导管相关静脉血栓形成后复发性血栓事件的预防
这项单中心回顾性研究纳入2003至2013年间373例有索引中心静脉导管相关静脉血栓(CVC-VTE)的19岁以下患者,评估二级预防疗效及复发危险因素。65例(17.4%)复发VTE,其中90.8%为CVC相关;全剂量抗凝与复发性CVC-VTE风险降低相关(OR 0.35),预防剂量无显著关联(OR 0.61)。
要点
- 每增加一根CVC、先天性心脏病、依赖全肠外营养与复发风险升高相关。
- 全剂量抗凝二级预防与复发性CVC-VTE风险降低相关(OR 0.35;95%CI 0.19-0.65)。
- 预防剂量抗凝与复发风险无显著关联(OR 0.61;95%CI 0.28-1.30)。
核心结论
- 有CVC-VTE的儿童复发VTE风险升高,全剂量抗凝二级预防与血栓事件风险降低65%相关。
研究设计与样本
- 单中心回顾性研究,纳入2003至2013年间373例19岁以下有索引CVC-VTE的患者。
主要发现
- 373例中239例(64.1%)后续置入CVC;65例(17.4%)复发VTE,其中59例(90.8%)为CVC相关。
- 多变量生存分析显示,每增加一根CVC(HR 12.00;95%CI 2.78-51.91)、先天性心脏病(HR 3.70;95%CI 1.97-6.95)、依赖全肠外营养(HR 4.02;95%CI 2.23-7.28)与复发风险升高相关。
- 全剂量抗凝二级预防与复发性CVC-VTE风险降低相关(OR 0.35;95%CI 0.19-0.65),预防剂量无显著关联(OR 0.61;95%CI 0.28-1.30)。
- 仅1.3%的CVC在预防剂量或全剂量抗凝下发生大出血。
临床怎么用
- 作者指出全剂量抗凝二级预防与复发性CVC-VTE风险降低65%相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Central venous catheters (CVC) are the most significant risk factor for pediatric venous thromboembolism (VTE). After an index CVC-associated VTE (CVC-VTE), the role of secondary prophylaxis for subsequent CVC placement is uncertain. Aims of this single-center retrospective study were to evaluate the efficacy of secondary prophylaxis for patients with a prior CVC-VTE and identify risk factors associated with recurrent VTE in patients less than 19 years with an index CVC-VTE between 2003 and 2013. Data collection included clinical and demographic factors, subsequent CVC placement, secondary prophylaxis strategy, recurrent VTE, and bleeding. Risk factors for recurrence and effectiveness of secondary prophylaxis were evaluated using survival and binomial models. Among 373 patients with an index CVC-VTE, 239 (64.1%) had subsequent CVC placement; 17.4% (65/373) of patients had recurrent VTE, of which 90.8% (59/65) were CVC-associated. On multivariable survival analysis, each additional CVC (hazards ratio [HR] 12.00; 95% confidence interval [CI] 2.78-51.91), congenital heart disease (HR 3.70; 95% CI 1.97-6.95), and total parenteral nutrition dependence (HR 4.02; 95% CI 2.23-7.28) were associated with an increased hazard of recurrence. Full dose anticoagulation for secondary prophylaxis was associated with decreased odds of recurrent CVC-VTE (odds ratio [OR] 0.35; 95% CI 0.19-0.65) but not prophylactic dosing (OR 0.61; 95% CI 0.28-1.30). Only 1.3% of CVCs experienced major bleeding with prophylactic or full-dose anticoagulation. In summary, children with CVC-VTE are at increased risk for recurrent VTE. Secondary prophylaxis with full-dose anticoagulation was associated with a 65% reduction in odds of thrombotic events.
引用
- Clark HH, Ballester L, Whitworth H, et al. Prevention of recurrent thrombotic events in children with central venous catheter-associated venous thrombosis. Blood. 2022. PMID: 34727184. doi:10.1182/blood.2021013453
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。